Hansa Biopharma announced the first commercial living donor kidney transplant in Australia using Idefirix (imlifidase), a treatment that helps highly sensitized patients overcome immune barriers to transplantation. This milestone is significant as it offers new hope to patients who face long waits and high risks due to pre-formed antibodies that complicate donor matching. The treatment is approved by Australia's Therapeutic Goods Administration for desensitization in kidney transplant candidates with positive cross-matches. Patient outcomes will be tracked in an Australian registry to gather real-world data and improve understanding of Idefirix's use in both living and deceased donor transplants.
Starting in 2026, Austrian crypto investors can request a standardized tax report from crypto service providers for income from 2025 onwards. This report details tax-relevant transactions and capital gains tax withheld, helping investors track income...
Bitcoin traders holding leveraged long positions face a critical liquidation risk at the $57,000 price level. This risk arises because if Bitcoin's price falls to this level, many leveraged long bets could be forcibly closed by exchanges due to insuf...
XRP is trading near $1, defending a key support level despite recent bearish pressure and a 280% spike in large transactions over $1 million, signaling possible institutional accumulation. The SEC is exploring moving U.S. equities onto blockchain for...
Strathcona is shifting its strategy from consolidation to developing brownfield projects, aiming to reach 300,000 barrels per day of oil production by 2035 without depending on high oil prices or big acquisitions. In Q2 2026, the company reported a r...
Ethereum rose 1.95% to $1,912, recovering above the key $1,900 level after finding support near $1,870. Technical indicators show bullish momentum with ETH trading above its 20-, 50-, and 100-day moving averages, though resistance remains near $2,000...
